logo
Share SHARE
FONT-SIZE Plus   Neg

Biotech Stocks Facing FDA Decision In May

Slide0-May-042417-lt.jpg

The month of April witnessed the FDA approving the first ever drug for tardive dyskinesia, a neurological disorder characterized by involuntary muscle movements.

The first to market tardive dyskinesia drug is Neurocrine Biosciences Inc.'s (NBIX) Ingrezza, and is expected to be launched on May 1, 2017. Not far behind, waiting to enter this niche market is Teva Pharmaceutical Industries Ltd's (TEVA) SD-809. This compound is under FDA priority review - with a decision date set for August 30, 2017.

So far this year, 14 novel drugs have been green-lighted by the FDA. A novel drug refers to a new molecular entity that has never before been approved anywhere in the world.

Now, let's take a look at some of the biotech stocks awaiting FDA decision in May.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT